 Aniracetam facilitates communication within the brain, improving the speed and operation of the mind
Numerous tests have proven that Aniracetam is one of the most potent nootropics, or ‘smart drugs’, currently available. Nootropic is the term used to describe drugs that act on the mind. The term was first used by Dr. Giurgea to describe a substance that was found to have beneficial effects in the treatment of memory loss, age related memory decline and lack of concentration.
Aniracetam is an analogue of Piracetam, purported to improve memory recall, reaction and detail. Like many of Piracetam's analogues, less Aniracetam is required (milligram dose per pound of body weight). But like Piracetam, Aniracetam has been found to be virtually non-toxic, with very few side effects and contraindications. Compared to Piracetam, Aniracetam has a more potent AMPA receptor enhancing effect, resulting in better focus and concentration.
One of the primary differences between nootropics and other 'memory enhancers’ is that nootropics improve communication across the brain's Corpus Callosum, the area of the brain that joins the left and right hemispheres. This cross-brain communication links the logical side of the brain with the creative side of the brain, allowing the user to draw on a greater potential of their mental ability.
Aniracetam is also considered to be a drug that can modulate the brain acetylcholine system. Findings show that Aniracetam administration significantly improves the cognitive function of patients with senile dementia of the Alzheimer type. The most likely explanation for this is that regular doses of Aniracetam has made a positive impact on the brain’s memory mechanism.
It also has a beneficial affect on the body as a whole, with improvements shown in users’ immune systems, increasing resistance to infection and generating a feeling of health and well-being, particularly in the elderly.
Another of Aniracetam's interesting properties is that its effects are very short-lived. After oral administration, the onset of activity is rapid and the total duration of activity is short. In rats, peak plasma levels of Aniracetam are reached 20-30 minutes after oral administration, and the half-life is 1.7-2.1 hours. In humans, the highest blood levels of the metabolites are reached two hours after administration, and this coincides with the largest changes in the EEG. Plasma levels of the metabolites reach baseline within 6 hours, although the half-life and AUC are both significantly increased in the elderly.
Like Piracetam, the dose-response curve for Aniracetam is bell-shaped. In rodents, effective doses are usually in the 10-100 mg/kg range, while the dose of Piracetam used in most rodent studies falls in the 100-600 mg/kg range. Also like Piracetam, a lower dose is required in primates to exert the same effect. The commonly recommended dose for clinical use is 1500 mg daily. A study comparing oral administration of 12.5, 25, and 50 mg/kg to monkeys found that all of the doses improved performance on a match-to-sample task, but the greatest effect was found at 25 mg/kg. In a study in the elderly, 1000 mg exerted greater EEG changes than 250 and 500 mg, as well as 2000 mg of Piracetam. The commonly recommended dose for nootropic use is 750-1500 mg, and this information supports that dosage range. Because of the short duration of activity, it would be ideal to take Aniracetam multiple times during the day.
Dosage: Take one or two 750mg tablets per day. Remember that all nootropics are synergistic with each other and with other brain nutrition products, (for example, choline, DMAE, hydergine, centrophenoxine.)
Safety: Aniracetam has been found to be virtually non-toxic, with very few side effects and contraindications.
When combining with other nootropic drugs the individual doses may have to be reduced in order to avoid possible side effects of nausea and headaches.
Persons taking prescription medication and pregnant or lactating women should consult a physician before using this product. Long-term use of this product should be supervised and monitored by a health care professional.
Disclaimer: This product and its statements have not been evaluated by the FDA. This product is not intended to treat, cure or prevent any disease. The above information is provided under the supplying company's terms and conditions and should not replace the advice of your personal physician.
Restrictions: This product is not available for shipment to the EU
CLICK HERE TO BUY
|
